Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

mine bitartrate are fully-compliant due to the drug's strict every-six hour dosing schedule and dose-limiting side effects, including gastrointestinal ("GI") problems such as stomach aches, nausea and vomiting.

Patrice Rioux, M.D., Ph.D., Raptor's Chief Medical Officer stated, "We are pleased that enrollment is now underway in our Phase 2b clinical trial in cystinosis. This is an underserved patient population and there is a compelling need for an improved treatment option. Many patients are unable to take adequate levels of the drug to halt the progression of their disease, which gradually destroys the organs in the body. We believe DR Cysteamine could have positive effects on the long-term health of cystinosis patients as well as the quality of life for patients, their families and caregivers."

Bruce Barshop, M.D., Ph.D., Professor of Clinical Pediatrics at UCSD and principal investigator for the cystinosis clinical trial, commented, "The initiation of this cystinosis trial offers us an opportunity to evaluate the potential for an improved treatment invented here at UCSD and further developed by Raptor. We're pleased to collaborate with Raptor in this effort to advance the standard of care in cystinosis."

About DR Cysteamine

DR Cysteamine is an enteric-coated micro-bead formulation of cysteamine bitartrate. Raptor obtained an exclusive, worldwide license to DR Cysteamine, as well as orphan drug designation from the FDA for DR Cysteamine for the treatment of nephropathic cystinosis, through its December 2007 acquisition of Encode Pharmaceuticals. In March 2008, Raptor acquired an exclusive worldwide license to intellectual property from the University of California, San Diego for use of cysteamine and DR Cysteamine for the treatment of non-alcoholic steatohepatitis ("NASH"), a progressive liver disease believed to affect 2-5% of the U.S. population. In October, 2008 Raptor ann
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
(Date:4/16/2015)... 16, 2015 Proove Biosciences , ... of BIO Contest for the 2015 BIO International ... 2015 BIO International Convention will take place June 15-18 ... the Buzz of BIO contest, industry leaders will be ... at the conference. The community voting period began on ...
(Date:4/16/2015)... IL (PRWEB) April 16, 2015 Regis ... the American Association for Cancer Research (AACR) annual meeting. ... Pennsylvania Convention Center, starting Saturday, April 18, in Philadelphia ... holds claim to title of the oldest and largest ... provides fellowships and grants, and partners with survivors to ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2
... 5:00 p.m. U.S. ET - EXTON, ... ) today announced that it will hold a conference call ... discuss fourth quarter and year end financials and an update ... portion and have the opportunity to pose questions, dial (866) ...
... ,Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... release its financial,results for the full year 2008 on ... (CET). To discuss these results, the Company will,conduct a ... The dial-in number for the ...
... Pa., Feb. 18 Jennifer Brownstein, Art ... named a 2009 Rising Star by the ... are up-and-coming professionals in various sectors of ... public relations, medical education, and market research. ...
Cached Biology Technology:Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan) 2AMT to Release Full Year 2008 Results on February 24, 2009 2Jennifer Brownstein, of CONNEXION Healthcare, Honored as 'Rising Star' by Healthcare Businesswomen's Association 2
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... MIT engineers have outfitted cells with tiny "backpacks" that could ... building blocks for tissue engineering. Michael Rubner, director of ... of a paper on the work that appeared online in ... this is the first time anyone has attached such a ...
... Nov. 6, 2008 -- Billions of tons of carbon sequestered ... atmosphere in the coming decades as a result of global ... peat bogs, water tables, and climate change. Such an ... locked away in the world,s peat bogs would dwarf emissions ...
... study highlights the role of a charge-switching enzyme in ... related neurological illness. Multiple sclerosis (MS) is ... insulator for electrical signaling in the nervous system ... nerve function. Much like the rubber insulation on ...
Cached Biology News:MIT creates tiny backpacks for cells 2Global warming predicted to hasten carbon release from peat bogs 2Multiple sclerosis research charges ahead with new mouse model of disease 2
... iTaq DNA polymerase is an ... for both conventional and real-time ... supplied at a concentration of ... includes 250 units polymerase, 1.25 ...
hnRNP U (H-94)...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up,and market it internationally. We work under ...
Biology Products: